Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
Hao Su,1,* Xiao Shang,1,* Hongruo Liu,2 Yutong Wang,1 Yang Yu,3 Yanhua Xu,4 Kui Jiang,2,* Fengzhi Feng1,* 1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chine...
Saved in:
Main Authors: | Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-02-01
|
Series: | International Journal of Women's Health |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-low-dose-lenvatinib-and-toripalimab-in-patients-peer-reviewed-fulltext-article-IJWH |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01) -
Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
by: Wang Caixia, et al.
Published: (2025-01-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01) -
The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)